

## EUROPEAN BODIES

### European Medicines Agency

- **Dedicated webpage on COVID-19** <sup>[1]</sup>  
EMA has put together a dedicated website which summarized information on COVID-19.
- **EMA Communication: Reporting suspected side effects of medicines in patients with COVID-19** <sup>[2]</sup>  
EMA and the national competent authorities are reminding healthcare professionals and patients with confirmed or suspected coronavirus disease (COVID-19) to report suspected side effects that they experience with any of the medicines they are taking.

### European Directorate for the Quality of Medicines & HealthCare (EDQM)

- **Information on licensed products as well as extemporaneous preparations which may be suitable for treatment of paediatric patients with COVID-19** <sup>[3]</sup>  
The European Paediatric Formulary Working Party at the EDQM compiled existing knowledge on paediatric formulations for active substances which are under investigation for the treatment of COVID-19 as well as known authorised medicinal products. This information might also be useful for other patient groups. Information on Chloroquine, Hydroxychloroquine and Lopinavir/Ritonavir is currently available.
- **EDQM's contributions to the protection of public health in the COVID-19 pandemic: latest information** <sup>[4]</sup>  
EDQM shared information on the preparedness of the Directorate as well as on information that has been made available to address the COVID-19 pandemic.

The disclaimer for the EAHP COVID-19 Resource Centre can be found [here](#) <sup>[5]</sup>

Last update: 17 November 2020

---

#### Links

[1] <https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19> [2] <https://www.ema.europa.eu/en/news/reporting-suspected-side-effects-medicines-patients->

covid-19 [3] <https://www.edqm.eu/en/news/products-and-extemporaneous-preparation-paediatric-formulations-may-be-useful-treatment-covid> [4] <https://www.edqm.eu/en/edqms-contributions-protection-public-health-covid-19-pandemic-latest-information#Pharmacopoeia%20and%20quality%20standards> [5] <https://www.eahp.eu/hp-practice/hospital-pharmacy/eahp-covid-19-resource-centre>